Meeting
2019 ASCO Annual Meeting
PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk non–muscle invasive bladder cancer.
Authors
Mathieu Roumiguie
Department of Urology Institut Universitaire du Cancer de Toulouse – Oncopole - Rangueil University, Toulouse, France
Mathieu Roumiguie , Eva Comperat , Yann Neuzillet , Francois-Xavier Nouhaud , Vivien Graffeille , Alexandra Masson-Lecomte , Pierre Colin , Francois Audenet , Nadine Houede , Stephane Larre , Evanguelos Xylinas , Jeanne PIana Thomassin , Juliette Cotte , Geraldine Pignot , Leonor Chaltiel , Morgan Roupret
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4550)
DOI
10.1200/JCO.2019.37.15_suppl.4550
Abstract #
4550
Poster Bd #
376
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Association of COX-2 expression with lymphocyte infiltration in colorectal cancer.
First Author: Zehua Wu
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2023 ASCO Annual Meeting
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.
First Author: Junjie Li
Poster
2022 ASCO Genitourinary Cancers Symposium
Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score.
First Author: Matt D. Galsky